Here Is The Easy Money-Making Trick Everyone Is Talking About! Learn More Here!
A breakthrough cancer drug called MOv18 IgE offers hope to patients who do not respond to existing treatments, according to research conducted by King’s College London and Guy’s and St Thomas’ NHS Foundation Trust.
The drug was found to shrink a tumor in a patient with ovarian cancer and was well tolerated by patients.
This study suggests that MOv18 IgE could pave the way for a new anti-cancer drug for individuals with chemotherapy-resistant cancers.
Immunotherapy, which stimulates the body’s natural defense system to attack cancer, was used in this research.
While existing antibody drugs belong to the IgG antibody type, this study tested the use of IgE antibodies in treating human cancer.
IgE antibodies are typically associated with allergic reactions but have also been shown to defend the body against certain parasitic infections.
This breakthrough research could potentially utilize IgE antibodies to attack cancerous cells and tumors.
The results of this study open up possibilities for the development of a new class of anti-cancer drugs.
This article was updated 10 months ago
